What Is Caplyta, and Why Does It Matter? Caplyta (lumateperone) is a once-daily oral medicine now approved to be used with antidepressants to treat major depressive disorder (MDD) in adults. It ...
Please provide your email address to receive an email when new articles are posted on . The clearance was based on a study in which adults with MDD used Rejoyn or a sham treatment app for 6 weeks. One ...
A new analysis included more than 110,000 adults with major depressive disorder (MDD) and treatment-resistant depression (TRD). Patients with TRD had total healthcare costs 1.5 times higher than those ...
Current Primary Outcome Measures •Percentage of Participants with Response (>=50 Percent improvement in MADRS total score from baseline) at Week 26 [ Time Frame: Week 26 ] -- Responders are defined as ...
The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously ...
IEEE Spectrum on MSN
At-home brain stimulation for depression is just the start
Flow’s headset is the first tDCS device approved by the FDA ...
Patients with asthma and major depressive disorder had more negative beliefs about their asthma, worse treatment adherence ...
How light deprivation, disrupted routines, and severe winter weather are impacting mental health across all ages LAS ...
About The Study: In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving behaviors than those in the control group without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results